If you’re attending the 10th LSX World Congress & are interested in learning about emerging technologies and therapies for #CardiometabolicDisease & #obesity, check out a panel featuring our CSO, Steffen-Sebastian Bolz, on April 29 at 2pm GMT. Learn more: brnw.ch/21wJ85k

We’re happy to announce we completed enrollment of our Phase 2 trial evaluating our lead candidate in individuals with #obesity and expanded the trial protocol to further explore circadian effects in weight loss treatment. Learn more here: brnw.ch/21wJat7

What an insightful panel at the LSX World Congress in London yesterday, where our CSO, Dr. Steffen-Sebastian Bolz, and other biotech leaders in the #obesity and #cardiometabolic space discussed approaches beyond GLP1 agonists and unique partnering opportunities for biotech.

Our CSO Steffen-Sebastian Bolz, M.D., Ph.D., spoke with Pharma Technology Focus about patient recruitment for #obesity trials and Aphaia’s successful strategy for its Phase 2 trial through close relationships with CRO partners and medical centers. Read more here: brnw.ch/21wJvi6

Check out this Drug Discovery World article featuring insights from our CSO Steffen-Sebastian Bolz’s, M.D., Ph.D., from the panel he participated in at the 10th LSX World Congress on #cardiometabolic disease, #obesity and partnering opportunities for biotech: brnw.ch/21wJxqT

Learn about our approach & other innovative modalities in #obesity & cardiometabolic therapy beyond “hormone replacement” in this Scrip, Citeline Commercial article by Andrew McConaghie, capturing insights from our panel participation at the 10th LSX World Congress: bit.ly/3UYldgy

On #ClinicalTrialsDay, we want to acknowledge our trial investigators who are tirelessly running our ongoing Phase 2 trials for #obesity & #prediabetes & recognize their commitment to supporting the well-being of patients. Learn more about this day here: bit.ly/4b4BCFX

#DYK metabolic disorders like #obesity & #Type2Diabetes have emerged as massive health and economic challenges due to calorie-rich diets, sedentary lifestyles and circadian disruptions? Learn more about our approach to treating #metabolic disorders here: bit.ly/3QIDxIL

We had an inspiring and productive time at our General Assembly meeting last week! We’re happy to have a great executive team leading our strategy to advance our lead candidate for #obesity & other metabolic diseases. Learn more about our approach: bit.ly/3V8eIXs

Read this Medscape article on oral weight loss drugs featuring our lead drug in development, which is designed to be released in the distal small intestine to restore nutrient-sensing pathways, regulating appetite, glucose metabolism & energy expenditure: wb.md/3XbAPyT

Today, we completed enrollment in Arm 2 (twice daily application scheme) of our Phase 2 trial evaluating the safety and efficacy of our lead candidate to induce weight loss in individuals with #obesity. Read the press release here: bit.ly/4clZxk7

We’re happy to announce that our Phase 2 study evaluating our lead candidate for the treatment of #prediabetes met its primary endpoint, significantly improving glucose tolerance in individuals with a pathological oral glucose tolerance test. Learn more: bit.ly/3XxrMbr

Check out this Endpoints News article featuring our CSO, Dr. Steffen-Sebastian Bolz, to learn more about the positive results from our Ph2 study evaluating our lead candidate for the treatment of #prediabetes to help prevent the progression to type 2 diabetes: bit.ly/3xqFRNk

Curious about the positive results from our Phase 2 trial on our oral glucose formulation for treating #prediabetes? Check out the study findings and the drug's mechanism of action in this New Atlas article: bit.ly/4csQZrV

Our CSO, Dr. Steffen-Sebastian Bolz, spoke with EmpoweredPatient on the #EmpoweredPatientPodcast about our ongoing Phase 2 trial in individuals with obesity, evaluating our lead drug in development, which is designed to restore metabolic balance. Listen here: bit.ly/4bkaVfJ

Our oral coated glucose formulation is designed to be released in the distal small intestine to reawaken nutrient-sensing cells that become less responsive in #obesity, restoring signaling pathways and metabolic balance. Learn more about our approach here: bit.ly/3V8eIXs

If you’re attending #SXSW 2025 and are interested in learning more about the #obesity space, vote for our panel exploring the future of weight management. Make a free profile and cast your vote before the deadline on Aug. 18. View our submission here: bit.ly/4fG7KCl

We're excited to see our Phase 2 trial evaluating our lead candidate in development featured as one of @BioSpace's top five #obesity readouts to watch this year! Check out the article here: bit.ly/3SOBvXJ

Our CSO, Steffen-Sebastian Bolz, MD, Ph.D., was featured on an episode of Xtalks Webinars Life Science Podcast, where he spoke about our innovative approach to treating metabolic conditions like #obesity and #prediabetes. Listen to the episode here: bit.ly/4g7c9OX

#DYK current treatments for #obesity often trigger side effects that may limit eligibility or long-term use? Our goal is to achieve a broad metabolic impact by restoring natural processes to offer efficacy while avoiding treatment side effects. Learn more: bit.ly/3QIDxIL